These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Durable complete responses in metastatic melanoma treated with interleukin-2 in combination with interferon alpha and chemotherapy.
    Author: Legha SS.
    Journal: Semin Oncol; 1997 Feb; 24(1 Suppl 4):S39-43. PubMed ID: 9122733.
    Abstract:
    Biochemotherapy, which uses recombinant interferon alpha (rIFN-alpha) and recombinant interleukin-2 (rIL-2) in combination with chemotherapy is a promising therapy for metastatic malignant melanoma. Various biochemotherapy regimens have produced overall objective response rates of > 50% and durable complete remission (CR) in approximately 10%-of treated patients. One such biochemotherapy regimen, consisting of sequential administration of cisplatin, vinblastine, and dacarbazine (CVD regimen) followed by rIFN-alpha and rIL-2, has produced a response rate of 60% and a CR rate of 20% in the most recent cohort of 62 patients treated at The University of Texas M.D. Anderson Cancer Center. The duration of partial responses with this and similar regimens typically averages 6 to 9 months; however, more than half of the CRs achieved with this regimen have been durable for 3+ to 5+ years. This has raised the possibility of long-term survival in approximately 10% of patients with metastatic melanoma. If confirmed, this will represent a significant advance in the treatment of metastatic melanoma.
    [Abstract] [Full Text] [Related] [New Search]